Table 1.
Demographics and clinical details of the patients with juvenile myoclonic epilepsy patients included in this study
Gender | Age | Age of onset | Myoclonic jerks per month | GTCSa per month | Recent seizure <1 year | Pharmacotherapyb |
---|---|---|---|---|---|---|
Male | 22 | 16 | 1 | 0 | Y | LEV 2000, VPA 2000 |
Female | 26 | 15 | 15 | 0.3 | Y | VPA 400, LMT 200, ZNS 400 |
Female | 45 | 7 | 0 | 0.1 | Y | LEV 1000, VPA 800 |
Male | 49 | 20 | 0 | 0 | N | LEV 1000, LMT 100, VPA 2000 |
Female | 39 | 12 | 100 | 0 | Y | VPA 400, LMT 450 |
Male | 36 | Teens | 0 | 0 | N | VPA 600 |
Female | 64 | 20 | 0 | 0 | N | LEV 2000 |
Female | 25 | 15 | 0 | 0 | N | LMT 200 |
Male | 25 | 11 | 0 | 0 | N | VPA 2400, LMT 300, ZNS 450 |
Female | 41 | 17 | 0 | 0 | Y | PHT 300 mg nocte, Metformine, Glucocide |
Female | 39 | 13 | 0 | 0 | N | LEV 1000, VPA 1000 |
Female | 22 | 14 | 4 | 0.4 | Y | LEV 1500, LMT 600 |
Female | 18 | 14 | Unknown | Unknown | Unknown | LEV 1000, VPA 1000 |
Female | 41 | 11 | 0.1 | 0 | Y | VPA 800, LEV 1000, CLB prn |
Female | 29 | 15 | 0 | 0 | N | VPA 2200, CLN 1 mg prn |
Female | 27 | 16 | 600 | 4 | Y | OXC 2100, CLB 25 |
Male | 40 | 16 | 0 | 0 | N | LMT 300 |
Male | 49 | 14 | 1 | 0.2 | Y | LEV 2000, VPA 800 |
Male | 36 | 16 | 0 | 0 | N | VPA 2000, LMT 150 |
Male | 29 | 16 | 0 | 0 | N | None for 1 year, had LEV before |
Male | 35 | 19 | 0 | 0 | N | VPA 1000 |
Male | 25 | 16 | 4 | 1 | Y | VPA 2000, LEV 1500 |
Female | 32 | Teens | 10 | 1 | Y | VPA 2000, CLB (as required) |
Male | 25 | Teens | 0 | 0 | N | VPA 600 |
Female | 32 | 16 | 0 | 0 | N | VPA 200, LMT 400 |
Female | 30 | 13 | 0 | 0 | N | LMT 400, LEV 250 |
Male | 32 | 13 | 0.1 | 0.1 | Y | VPA 2000, LMT 400, LEV 500 |
Male | 32 | 16 | 0 | 0 | N | VPA 2000 |
CLB = clobazam; CLN = clonazepam; GTCS = generalized tonic clonic seizures; LEV = levetiracetam; LMT = lamotrigine; PHT = phenytoin; prn = pro re nata; VPA = valproate.